203 related articles for article (PubMed ID: 21718522)
1. Safety and efficacy of miltefosine alone and in combination with sodium stibogluconate and liposomal amphotericin B for the treatment of primary visceral leishmaniasis in East Africa: study protocol for a randomized controlled trial.
Omollo R; Alexander N; Edwards T; Khalil EA; Younis BM; Abuzaid AA; Wasunna M; Njoroge N; Kinoti D; Kirigi G; Dorlo TP; Ellis S; Balasegaram M; Musa AM
Trials; 2011 Jun; 12():166. PubMed ID: 21718522
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of AmBisome in Combination with Sodium Stibogluconate or Miltefosine and Miltefosine Monotherapy for African Visceral Leishmaniasis: Phase II Randomized Trial.
Wasunna M; Njenga S; Balasegaram M; Alexander N; Omollo R; Edwards T; Dorlo TP; Musa B; Ali MH; Elamin MY; Kirigi G; Juma R; Kip AE; Schoone GJ; Hailu A; Olobo J; Ellis S; Kimutai R; Wells S; Khalil EA; Strub Wourgaft N; Alves F; Musa A
PLoS Negl Trop Dis; 2016 Sep; 10(9):e0004880. PubMed ID: 27627654
[TBL] [Abstract][Full Text] [Related]
3. Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial.
Sundar S; Sinha PK; Rai M; Verma DK; Nawin K; Alam S; Chakravarty J; Vaillant M; Verma N; Pandey K; Kumari P; Lal CS; Arora R; Sharma B; Ellis S; Strub-Wourgaft N; Balasegaram M; Olliaro P; Das P; Modabber F
Lancet; 2011 Feb; 377(9764):477-86. PubMed ID: 21255828
[TBL] [Abstract][Full Text] [Related]
4. New treatment approach in Indian visceral leishmaniasis: single-dose liposomal amphotericin B followed by short-course oral miltefosine.
Sundar S; Rai M; Chakravarty J; Agarwal D; Agrawal N; Vaillant M; Olliaro P; Murray HW
Clin Infect Dis; 2008 Oct; 47(8):1000-6. PubMed ID: 18781879
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of short course combination regimens with AmBisome, miltefosine and paromomycin for the treatment of visceral leishmaniasis (VL) in Bangladesh.
Rahman R; Goyal V; Haque R; Jamil K; Faiz A; Samad R; Ellis S; Balasegaram M; Boer MD; Rijal S; Strub-Wourgaft N; Alves F; Alvar J; Sharma B
PLoS Negl Trop Dis; 2017 May; 11(5):e0005635. PubMed ID: 28558062
[TBL] [Abstract][Full Text] [Related]
6. Assessing the Efficacy and Safety of Liposomal Amphotericin B and Miltefosine in Combination for Treatment of Post Kala-Azar Dermal Leishmaniasis.
Ramesh V; Dixit KK; Sharma N; Singh R; Salotra P
J Infect Dis; 2020 Feb; 221(4):608-617. PubMed ID: 31854451
[TBL] [Abstract][Full Text] [Related]
7. A comparison of miltefosine and sodium stibogluconate for treatment of visceral leishmaniasis in an Ethiopian population with high prevalence of HIV infection.
Ritmeijer K; Dejenie A; Assefa Y; Hundie TB; Mesure J; Boots G; den Boer M; Davidson RN
Clin Infect Dis; 2006 Aug; 43(3):357-64. PubMed ID: 16804852
[TBL] [Abstract][Full Text] [Related]
8. Combination Therapy Against Indian Visceral Leishmaniasis with Liposomal Amphotericin B (Fungisome
Goswami RP; Rahman M; Das S; Tripathi SK; Goswami RP
Am J Trop Med Hyg; 2020 Jul; 103(1):308-314. PubMed ID: 32394874
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of paromomycin/miltefosine/liposomal amphotericin B combinations for the treatment of post-kala-azar dermal leishmaniasis in Sudan: A phase II, open label, randomized, parallel arm study.
Younis BM; Mudawi Musa A; Monnerat S; Abdelrahim Saeed M; Awad Gasim Khalil E; Elbashir Ahmed A; Ahmed Ali M; Noureldin A; Muthoni Ouattara G; Nyakaya GM; Teshome S; Omollo T; Ochieng M; Egondi T; Mmbone M; Chu WY; Dorlo TPC; Zijlstra EE; Wasunna M; Alvar J; Alves F
PLoS Negl Trop Dis; 2023 Nov; 17(11):e0011780. PubMed ID: 37988402
[TBL] [Abstract][Full Text] [Related]
10. Miltefosine in children with visceral leishmaniasis: a prospective, multicentric, cross-sectional study.
Singh UK; Prasad R; Mishra OP; Jayswal BP
Indian J Pediatr; 2006 Dec; 73(12):1077-80. PubMed ID: 17202633
[TBL] [Abstract][Full Text] [Related]
11. Paromomycin and Miltefosine Combination as an Alternative to Treat Patients With Visceral Leishmaniasis in Eastern Africa: A Randomized, Controlled, Multicountry Trial.
Musa AM; Mbui J; Mohammed R; Olobo J; Ritmeijer K; Alcoba G; Muthoni Ouattara G; Egondi T; Nakanwagi P; Omollo T; Wasunna M; Verrest L; Dorlo TPC; Musa Younis B; Nour A; Taha Ahmed Elmukashfi E; Ismail Omer Haroun A; Khalil EAG; Njenga S; Fikre H; Mekonnen T; Mersha D; Sisay K; Sagaki P; Alvar J; Solomos A; Alves F
Clin Infect Dis; 2023 Feb; 76(3):e1177-e1185. PubMed ID: 36164254
[TBL] [Abstract][Full Text] [Related]
12. Drug combinations for visceral leishmaniasis.
Olliaro PL
Curr Opin Infect Dis; 2010 Dec; 23(6):595-602. PubMed ID: 20871400
[TBL] [Abstract][Full Text] [Related]
13. [Treatment of visceral leishmaniasis in children].
Minodier P; Noël G; Blanc P; Uters M; Retornaz K; Garnier JM
Med Trop (Mars); 2007 Feb; 67(1):73-8. PubMed ID: 17506279
[TBL] [Abstract][Full Text] [Related]
14. Sodium stibogluconate (SSG) & paromomycin combination compared to SSG for visceral leishmaniasis in East Africa: a randomised controlled trial.
Musa A; Khalil E; Hailu A; Olobo J; Balasegaram M; Omollo R; Edwards T; Rashid J; Mbui J; Musa B; Abuzaid AA; Ahmed O; Fadlalla A; El-Hassan A; Mueller M; Mucee G; Njoroge S; Manduku V; Mutuma G; Apadet L; Lodenyo H; Mutea D; Kirigi G; Yifru S; Mengistu G; Hurissa Z; Hailu W; Weldegebreal T; Tafes H; Mekonnen Y; Makonnen E; Ndegwa S; Sagaki P; Kimutai R; Kesusu J; Owiti R; Ellis S; Wasunna M
PLoS Negl Trop Dis; 2012; 6(6):e1674. PubMed ID: 22724029
[TBL] [Abstract][Full Text] [Related]
15. A randomized trial of AmBisome monotherapy and AmBisome and miltefosine combination to treat visceral leishmaniasis in HIV co-infected patients in Ethiopia.
Diro E; Blesson S; Edwards T; Ritmeijer K; Fikre H; Admassu H; Kibret A; Ellis SJ; Bardonneau C; Zijlstra EE; Soipei P; Mutinda B; Omollo R; Kimutai R; Omwalo G; Wasunna M; Tadesse F; Alves F; Strub-Wourgaft N; Hailu A; Alexander N; Alvar J
PLoS Negl Trop Dis; 2019 Jan; 13(1):e0006988. PubMed ID: 30653490
[TBL] [Abstract][Full Text] [Related]
16. A comparison of liposomal amphotericin B with sodium stibogluconate for the treatment of visceral leishmaniasis in pregnancy in Sudan.
Mueller M; Balasegaram M; Koummuki Y; Ritmeijer K; Santana MR; Davidson R
J Antimicrob Chemother; 2006 Oct; 58(4):811-5. PubMed ID: 16916865
[TBL] [Abstract][Full Text] [Related]
17. A randomized, open-label study to evaluate the efficacy and safety of liposomal amphotericin B (AmBisome) versus miltefosine in patients with post-kala-azar dermal leishmaniasis.
Pandey K; Pal B; Siddiqui NA; Lal CS; Ali V; Bimal S; Kumar A; Verma N; Das VNR; Singh SK; Topno RK; Das P
Indian J Dermatol Venereol Leprol; 2021; 87(1):34-41. PubMed ID: 33580944
[TBL] [Abstract][Full Text] [Related]
18. Oral miltefosine for Indian visceral leishmaniasis.
Sundar S; Jha TK; Thakur CP; Engel J; Sindermann H; Fischer C; Junge K; Bryceson A; Berman J
N Engl J Med; 2002 Nov; 347(22):1739-46. PubMed ID: 12456849
[TBL] [Abstract][Full Text] [Related]
19. Magnitude of unresponsiveness to sodium stibogluconate in the treatment of visceral leishmaniasis in Bihar.
Das VN; Ranjan A; Bimal S; Siddique NA; Pandey K; Kumar N; Verma N; Singh VP; Sinha PK; Bhattacharya SK
Natl Med J India; 2005; 18(3):131-3. PubMed ID: 16130613
[TBL] [Abstract][Full Text] [Related]
20. Single-dose liposomal amphotericin B (AmBisome®) for the treatment of visceral leishmaniasis in East Africa: study protocol for a randomized controlled trial.
Edwards T; Omollo R; Khalil EA; Yifru S; Musa B; Musa A; Wasunna M; Smith PG; Royce C; Ellis S; Balasegaram M; Hailu A
Trials; 2011 Mar; 12():66. PubMed ID: 21375777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
